Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Genmab A/S Share Price

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen
Other stock markets
 16:20:00 04/12/2024 GMT 		5-day change 1st Jan Change
1,528.50 DKK -0.20% Intraday chart for Genmab A/S +4.87% -29.07%
01:58pm Scancell Signs New Commercial License Deal With Genmab MT
08:00am Scancell Holdings plc Announces Genmab Exercises Option to A Second Commercial License Agreement CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site

Valuation: Genmab A/S

Capitalization 97.27B 13.74B 13.05B 12.13B 10.8B 19.33B 1,164B 21.34B 150B 55.8B 477B 51.59B 50.46B 2,063B P/E ratio 2024 *
18.5x
P/E ratio 2025 * 16.6x
Enterprise value 80.3B 11.34B 10.77B 10.02B 8.92B 15.96B 961B 17.62B 124B 46.07B 394B 42.59B 41.66B 1,703B EV / Sales 2024 *
3.79x
EV / Sales 2025 * 2.91x
Free-Float
95.95%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Genmab A/S

Dynamic Chart

Latest news: Genmab A/S

Scancell Signs New Commercial License Deal With Genmab 12:58pm MT
Scancell Holdings plc Announces Genmab Exercises Option to A Second Commercial License Agreement 07:00am CI
Genmab A/S Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 02:30 PM 12-03
JP Morgan lowers target price for Genmab to DKK 1,700 (2,050), reiterates neutral - BN 12-03 FW
Jefferies lowers target price for Genmab to DKK 1,650 (2,150), reiterates Hold 11-25 FW
Goldman Sachs lowers target price for Genmab to DKK 2,425 (2,509), reiterates neutral - BN 11-20 FW
Trump-induced Pharma fears shouldn't be long-lived 11-19Alphavalue
Genmab A/S Presents at Jefferies London Healthcare Conference 2024, Nov-19-2024 03:30 PM 11-19
Deutsche Bank lowers target price for Genmab to DKK 2,250 (2,500), reiterates Buy 11-12 FW
Carnegie lowers target price for Genmab to DKK 2,658 (2,740), reiterates Buy - BN 11-12 FW
Johnson & Johnson Unit Seeks US, EU Approval for New Indication of Multiple Myeloma Treatment 11-08 MT
GENMAB : Q3 profitability beat; lower end of the guidance upgraded 11-07Alphavalue
Global markets live: Qualcomm, ARM, Lyft, AppLovin, AstraZeneca... 11-07Our Logo
More news

Last Transcript: Genmab A/S

Logo Genmab A/S
Genmab A/S Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 02:30 PM
12-03
More transcripts

Analysts' recommendations: Genmab A/S

JP Morgan lowers target price for Genmab to DKK 1,700 (2,050), reiterates neutral - BN 12-03 FW
Jefferies lowers target price for Genmab to DKK 1,650 (2,150), reiterates Hold 11-25 FW
Goldman Sachs lowers target price for Genmab to DKK 2,425 (2,509), reiterates neutral - BN 11-20 FW
Deutsche Bank lowers target price for Genmab to DKK 2,250 (2,500), reiterates Buy 11-12 FW
Carnegie lowers target price for Genmab to DKK 2,658 (2,740), reiterates Buy - BN 11-12 FW
More recommendations

Press Releases: Genmab A/S

Genmab A/S : Current Report by Foreign Issuer (Form 6-K) 04:31pm PU
Genmab A/S : has published its Articles of Association 01:46pm PU
COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants Form 6 K 12-03 PU
Capital Increase in Genmab as a Result of Employee Warrant Exercise 12-03 GL
Genmab A/S : Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Form 6 K 12-03 PU
More press releases

News in other languages: Genmab A/S

En Direct des marchés : Pluie de résultats en Europe, Qualcomm brille aux Etats-Unis 11-07
Comme un air de déjà-vu 11-07
La bourse chinoise fait n'importe quoi 10-08
Avis d'analystes du jour : Hermès, Crédit Agricole, Nexans, Orange, Rémy Cointreau, STMicro, Ubisoft... 10-08
OPINIONI DEGLI ANALISTI DEL GIORNO: Recordati, Brembo, Hermès, Italgas, Crédit Agricole, Amplifon, Aena, Rémy Cointreau, STMicro, Cellnex... 10-08
More news

Quotes and Performance

1 day+0.02%
1 week+2.72%
Current month+0.16%
1 month-1.55%
3 months-18.11%
6 months-21.11%
Current year-29.07%
More quotes

Course Extremes

1 week
1 491.00
Extreme 1491
1 567.00
1 month
1 431.00
Extreme 1431
1 652.00
Current year
1 431.00
Extreme 1431
2 227.00
1 year
1 431.00
Extreme 1431
2 283.00
3 years
1 431.00
Extreme 1431
3 327.00
5 years
1 082.50
Extreme 1082.5
3 327.00
10 years
301.70
Extreme 301.7
3 327.00
More quotes

Managers and Directors: Genmab A/S

Director TitleAgeSince
Jan van de Winkel CEO
 Chief Executive Officer 63 31/05/2010
Anthony Pagano DFI
 Director of Finance/CFO 46 29/02/2020
Rayne Waller CTO
 Chief Tech/Sci/R&D Officer - 15/08/2024
Manager TitleAgeSince
Anders Gersel Pedersen BRD
 Director/Board Member 73 31/10/2003
Pernille Erenbjerg BRD
 Director/Board Member 57 31/12/2014
Paolo Augusto Paoletti BRD
 Director/Board Member 73 31/12/2014
More insiders

ETFs: Genmab A/S

Name Weight AuM 1st Jan change Investor Rating
XACT NORDEN (UCITS ETF) - SEK ETF XACT NORDEN (UCITS ETF) - SEK
3.64% 203 M€ +14.09%
HAN-GINS TECH MEGATREND EQUAL WEIGHT UCITS ETF - USD ETF HAN-GINS Tech Megatrend Equal Weight UCITS ETF - USD
1.01% 83 M€ +19.13%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
0.75% 20 M€ +16.48% -
VANECK SUSTAINABLE WORLD EQUAL WEIGHT UCITS ETF - EUR ETF VanEck Sustainable World Equal Weight UCITS ETF - EUR
0.56% 772 M€ +17.55%
More ETFs: Genmab A/S

Bio Therapeutic Drugs

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
GENMAB A/S Stock Genmab A/S
-0.20%+2.72%-30.40%-37.00%13.7B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+0.58%-1.07%+31.07%+124.12%118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.14%-0.41%-8.69%+20.29%80.65B
ARGENX SE Stock argenx SE
+0.27%+1.27%+40.00%+136.58%37.33B
BIONTECH SE Stock BioNTech SE
-0.32%-4.65%+15.21%-58.86%27.71B
BEIGENE, LTD. Stock BeiGene, Ltd.
-2.12%-1.83%+11.71%-32.36%21.89B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-1.61%+5.06%-37.98%-63.70%20.55B
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
-1.77%-7.77%+676.39%+247.29%13.1B
INSMED INCORPORATED Stock Insmed Incorporated
+2.64%-2.22%+175.10%+176.74%12.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.65%-0.17%+8.44%+56.61%12.7B
Average -0.15%+0.19%+88.09%+56.97% 35.83B
Weighted average by Cap. +0.05%+0.07%+42.34%+65.41%
See all sector performances

Financials

2024 *2025 *
Net sales 21.18B 2.99B 2.84B 2.64B 2.35B 4.21B 253B 4.65B 32.69B 12.15B 104B 11.23B 10.99B 449B 24.76B 3.5B 3.32B 3.09B 2.75B 4.92B 296B 5.43B 38.22B 14.2B 121B 13.13B 12.84B 525B
Net income 5.48B 773M 734M 683M 608M 1.09B 65.51B 1.2B 8.45B 3.14B 26.87B 2.9B 2.84B 116B 6.24B 882M 837M 779M 693M 1.24B 74.7B 1.37B 9.64B 3.58B 30.64B 3.31B 3.24B 132B
Net Debt -16.98B -2.4B -2.28B -2.12B -1.89B -3.37B -203B -3.72B -26.2B -9.74B -83.31B -9B -8.81B -360B -25.25B -3.57B -3.39B -3.15B -2.8B -5.02B -302B -5.54B -38.98B -14.49B -124B -13.39B -13.1B -536B
More financial data * Estimated data

Company Profile

Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
Employees
2,635
Sector
Biotechnology & Medical Research
Calendar
06/12/2024 - American Society of Hematology Meeting - Abstract No: 7802
More about the company

Quotes

Date Price Change Volume
04/12/24 1,528.50 kr -0.20% 98,222
03/12/24 1,531.50 kr -1.29% 82,092
02/12/24 1,551.50 kr +1.67% 107,473
29/11/24 1,526.00 kr +0.99% 128,094
28/11/24 1,511.00 kr +1.55% 50,313

Delayed Quote Nasdaq Copenhagen, December 04, 2024 at 04:20 pm

More quotes

Income Statement and Estimates

income-statement-evolution-chart GENMAB-A-S More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
A-
surperformance-ratings-light-chart GENMAB-A-SMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
1,531.50DKK
Average target price
2,345.00DKK
Spread / Average Target
+53.12%
Consensus
Profit revisions
estimates-change-chart GENMAB-A-S Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart GENMAB-A-S Company calendar
  1. Stock Market
  2. Equities
  3. GMAB Stock
Exceptional Extension | BLACK FRIDAY -40% : Unlock Tomorrow's Top Investments with Our Exclusive Subscriber-Only Tools!
d
:
:
BENEFIT NOW
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition